The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing Manufacture Of Chemicals And Pharamceuticals Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
170 jobs Number of planned job losses
Announcement Date
8 January 2004
Employment effect (start)
Foreseen end date
Description
Schering-Plough manufactures anti-cancer and anti-viral drugs known as 'interferon'. The 170 job losses are being attributed to rationalisation and a major fall in sales of anti-caner drugs. The cuts follow a recent announcement by the parent company of a 10% reduction in wage costs worldwide. Most of those affected will be contract workers, and it is hoped that remaining cuts affecting permanent staff can be achieved through voluntary redundancies. The company is to negotiate a redundancy package with the union SIPTU.
Sources
8 January 2004: The Irish Examiner
8 January 2004: The Irish Times
Citation
Eurofound (2004), Schering-Plough, Internal restructuring in Ireland, factsheet number 59527, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/59527.
Digitisation and automation technologies, including artificial intelligence (AI), can affect working conditions in a variety of ways and their use in the workplace raises a host of new ethical concerns.
The retail banking sector is fertile ground for studying the impacts of digitalisation on work and employment. Financial services are increasingly provided online, without the intermediary of customer-facing institutions.
European labour markets have recovered strongly from COVID-19. By the end of 2021, little more than 18 months after the start of the pandemic, employment rates in the EU were almost at pre-crisis levels.
